- Home
- IMUX
IMUX
Immunic Inc.
as 05-30-2025 4:00pm EST
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 107.3M | IPO Year: | N/A |
| Target Price: | $11.60 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.96 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.56 - $2.11 | Next Earning Date: | 05-15-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Immunic Inc. News
IMUX Breaking Stock News: Dive into IMUX Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Immunic Tumbles After Pricing $65 Million Offering of Warrants
PR Newswire
3 days ago
Immunic, Inc. Announces Pricing of Oversubscribed $65 Million Underwritten Public Offering
MT Newswires
3 days ago
Immunic Begins Underwritten Public Offering
PR Newswire
3 days ago
Immunic, Inc. Announces Proposed Public Offering
MT Newswires
9 days ago
B. Riley Cuts Price Target on Immunic to $5 From $6, Keeps Buy Rating
Associated Press Finance
16 days ago
Immunic: Q1 Earnings Snapshot
PR Newswire
a month ago
Immunic to Participate in Scientific and Industry Conferences in May
Clinical Trials Arena
a month ago
Immunic presses ahead with MS drug despite Phase II endpoint miss
Compare IMUX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IMUX Immunic Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.